Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
详细信息 查看全文
- 作者：Shinya Hirabara (1) (2)
Nobunori Takahashi (1)
Naoki Fukaya (3)
Hiroyuki Miyake (4)
Yuichiro Yabe (5)
Atsushi Kaneko (6)
Takayasu Ito (7)
Takeshi Oguchi (8)
Daihei Kida (6)
Yuji Hirano (2)
Takayoshi Fujibayashi (9)
Fumiaki Sugiura (8)
Masatoshi Hayashi (10)
Koji Funahashi (1)
Masahiro Hanabayashi (1)
Shuji Asai (1)
Naoki Ishiguro (1)
Toshihisa Kojima (1) - 关键词：Abatacept ; Etanercept ; Rheumatoid arthritis ; Switching medications ; Tocilizumab
- 刊名：Clinical Rheumatology
- 出版年：2014
- 出版时间：September 2014
- 年：2014
- 卷：33
- 期：9
- 页码：1247-1254
- 全文大小：445 KB
- 参考文献：1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903-11. doi:10.1016/S0140-6736(01)06075-5 CrossRef
2. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, investigators Ts (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675-81. doi:10.1016/S0140-6736(04)15640-7 CrossRef
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400-411. doi:10.1002/art.20217 CrossRef
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study G (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594-602. doi:10.1056/NEJM200011303432202 CrossRef
5. Ostergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS, Petri A, Andersen LS, Tarp U, Hansen A, Hjardem E, Hetland ML (2007) Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 36(2):151-54. doi:10.1080/03009740601089267 CrossRef
6. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-75. doi:10.1136/ard.2009.126532 CrossRef
7. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML, all departments of rheumatology in D (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(7):1216-222. doi:10.1136/ard.2010.140129 CrossRef
8. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rodgaard A, Skot J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML (2007) Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66(9):1184-189. doi:10.1136/ard.2006.054742 CrossRef
9. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552-563. doi:10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W CrossRef
10. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y (2012) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 22(4):498-08. doi:10.1007/s10165-011-0541-5 CrossRef
11. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H (2012) Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 22(3):327-38. doi:10.1007/s10165-011-0516-6 CrossRef
12. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y (2013) Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202433
13. Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, Dodge R, Aranda R (2007) Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 34(12):2365-373
14. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162-167. doi:10.1136/ard.2006.068064 CrossRef
15. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70(2):266-71. doi:10.1136/ard.2010.132134 CrossRef
16. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56(1):13-0. doi:10.1002/art.22331 CrossRef
17. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, Group CS (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54(9):2817-829. doi:10.1002/art.22033 CrossRef
18. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N (2012) Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol 22(3):370-75. doi:10.1007/s10165-011-0528-2 CrossRef
19. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T (2011) Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21(2):122-33. doi:10.1007/s10165-010-0366-7 CrossRef
20. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516-523. doi:10.1136/ard.2008.092932 CrossRef
21. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19(1):12-9. doi:10.1007/s10165-008-0125-1 CrossRef
22. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096-103. doi:10.1136/ard.2007.080002 CrossRef
23. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, Investigators O (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617):987-97. doi:10.1016/S0140-6736(08)60453-5 CrossRef
24. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N, Tbc (2012) Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol 22(3):339-45. doi:10.1007/s10165-011-0518-4 CrossRef
25. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67(4):547-54. doi:10.1136/ard.2007.074773 CrossRef
26. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW (2011) Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 38(7):1273-281. doi:10.3899/jrheum.101142 CrossRef - 作者单位：Shinya Hirabara (1) (2)
Nobunori Takahashi (1)
Naoki Fukaya (3)
Hiroyuki Miyake (4)
Yuichiro Yabe (5)
Atsushi Kaneko (6)
Takayasu Ito (7)
Takeshi Oguchi (8)
Daihei Kida (6)
Yuji Hirano (2)
Takayoshi Fujibayashi (9)
Fumiaki Sugiura (8)
Masatoshi Hayashi (10)
Koji Funahashi (1)
Masahiro Hanabayashi (1)
Shuji Asai (1)
Naoki Ishiguro (1)
Toshihisa Kojima (1)
1. Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, Japan
2. Department of Rheumatology, Toyohashi Municipal Hospital, 50 Hachiken-nishi, Aotake-cho, Toyohashi, Japan
3. Department of Orthopedic Surgery, Kariya-Toyota General Hospital, 5-15 Sumiyoshi-cho, Kariya, Japan
4. Department of Orthopedic Surgery, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Japan
5. Department of Rheumatology, Tokyo Shinjuku Medical Center, Tsukudo-cho, Shinjuku-ku, Tokyo, Japan
6. Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, Aichi, Japan
7. Ito Orthopedic Clinic, 3-812 Ueda-minami, Tenpaku-ku, Nagoya, Aichi, Japan
8. Department of Orthopedic Surgery, Anjo Kosei Hospital, 28 Higashihirokute, Anjo, Japan
9. Department of Orthopedic Surgery, Konan Kosei Hospital, 137 Oomatsubara, Takaya-cho, Konan, Aichi, Japan
10. Department of Rheumatology, Nagano Red Cross Hospital, 5-22-1 Wakazato, Nagano, Japan - ISSN：1434-9949
文摘
The aim of this study was to compare the efficacy and retention rates of three biologics (abatacept, tocilizumab, and etanercept) after switching from first-course anti-TNF monoclonal antibody therapy. We performed a retrospective multicenter study of 89 patients who underwent second-course biologic therapy for 52?weeks after switching from first-course anti-TNF monoclonal antibody therapy. Patients at baseline had a mean age of 58.7?years, mean disease duration of 9.8?years, and mean clinical disease activity index (CDAI) of 22.4. There was no significant difference between the three drugs, except in rheumatoid factor positivity. Retention rates for abatacept, tocilizumab, and etanercept treatment at 52?weeks were 72.0, 89.5 and 84.6?%, respectively. The evaluation of CDAI indicated no significant difference at 52?weeks among the three drugs. Discontinuation due to all unfavorable causes did not significantly differ among the three drugs in hazard ratio-based evaluations. Our results show that patients treated with abatacept, tocilizumab, and etanercept achieved a high response rate with no significant differences in drug retention rates and clinical efficacy. These drugs represent good therapeutic options for patients with RA who are refractory to anti-TNF monoclonal antibody therapy.